Compile Data Set for Download or QSAR
Report error Found 146 Enz. Inhib. hit(s) with all data for entry = 12473
Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704858((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  0.657nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704878(N-(4-(azetidin-3-yloxy)-3-(3,5-dimethylisoxazol-4-...)
Affinity DataKi:  0.850nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704873((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  0.907nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704876(N-(4-(azetidin-3-yloxy)-3-(3,5-dimethylisoxazol-4-...)
Affinity DataKi:  1.07nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704828(N-[3-(3,5-dimethylisoxazol-4-yl)-4-[2-(2- methoxye...)
Affinity DataKi:  1.08nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704823(N-[3-(3,5-dimethylisoxazol-4-yl)-4-(2- morpholinoe...)
Affinity DataKi:  1.08nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704747((1S,2R)-N-[3-(3,5-dimethylisoxazol-4-yl)-4-(2-pyrr...)
Affinity DataKi:  1.13nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704864(N-[3-(3,5-dimethylisoxazol-4-yl)-4-[2-(2- methoxye...)
Affinity DataKi:  1.14nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704814((1S,2R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(((R)-p...)
Affinity DataKi:  1.19nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704867((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  1.21nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704870(N-(4-(azetidin-3-yloxy)-3-(3,5-dimethylisoxazol-4-...)
Affinity DataKi:  1.36nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704838((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  1.53nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704811(N-[3-(3,5-dimethylisoxazol-4-yl)-4-[2-[(1R,5S)-3-o...)
Affinity DataKi:  1.61nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704856((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  1.64nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704879((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  1.69nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704880(N-(4-(azetidin-3-yloxy)-3-(3,5-dimethylisoxazol-4-...)
Affinity DataKi:  2.05nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704874(N-(4-(azetidin-3-yloxy)-3-(3,5-dimethylisoxazol-4-...)
Affinity DataKi:  2.10nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704831(N-[3-(3,5-dimethylisoxazol-4-yl)-4-[[(2R)-2- piper...)
Affinity DataKi:  2.16nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704763(N-(3-(3,5-dimethylisoxazol-4-yl)-4-(2-(pyrrolidin-...)
Affinity DataKi:  2.60nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704761(N-[3-(3,5-dimethylisoxazol-4-yl)-4-(2-pyrrolidin-1...)
Affinity DataKi:  2.66nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704820((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  2.69nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704738(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(3,5-dimethylisox...)
Affinity DataKi:  2.70nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704735(N-(3-(3,5-dimethylisoxazol-4-yl)-4-(2-(pyrrolidin-...)
Affinity DataKi:  2.89nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704871((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  2.92nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704861((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  3.05nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704840((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  3.18nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704845(N -(3-(3,5-dimethylisoxazol-4-yl)-4-(((R)-piperidi...)
Affinity DataKi:  3.40nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704866((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(pyrrolidin...)
Affinity DataKi:  3.61nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704753(N-(3-(3,5-dimethylisoxaozl-4-yl)-4-(2-(pyrrolidin-...)
Affinity DataKi:  3.78nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704854((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  3.86nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704812((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  3.92nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704745(4-chloro-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(2-(py...)
Affinity DataKi:  3.94nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704808((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  4.01nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704813(N-(4-(2-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5...)
Affinity DataKi:  4.07nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704875((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  4.22nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704788(N-[3-(3,5-dimethylisoxazol-4-yl)-4-[[(2R)-2- piper...)
Affinity DataKi:  4.22nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704810((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  4.5nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704744(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(3,5-dimethylisox...)
Affinity DataKi:  4.5nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704736(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(3,5-dimethylisox...)
Affinity DataKi:  4.67nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704877((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  4.68nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704817(N-[3-(3,5-dimethylisoxazol-4-yl)-4-[2-[(1S,4S)-2-o...)
Affinity DataKi:  4.70nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704848(N-(3-(3,5-dimethylisoxazol-4-yl)-4-(((R)-piperidin...)
Affinity DataKi:  4.72nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704859((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  4.73nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704869((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  4.85nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704818((1S,2S)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(((R)-p...)
Affinity DataKi:  4.91nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704785(N-(3-(3,5-dimethylisoxazol-4-yl)-4-(2-(4-hydroxypi...)
Affinity DataKi:  5.08nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704800((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(piperidin-...)
Affinity DataKi:  5.09nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704746(N-(4-(2-(azetidin-1-yl)ethoxy)-3-(3,5-dimethylisox...)
Affinity DataKi:  5.28nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704830(N-(4-(2-acetimidamido)-3-(3,5-dimethylisoxazol-4- ...)
Affinity DataKi:  5.39nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Arena Pharmaceuticals

US Patent
LigandPNGBDBM704783((R)-N-(3-(3,5-dimethylisoxazol-4-yl)-4-(2-(3- meth...)
Affinity DataKi:  5.51nMAssay Description:Radioligand binding assays were performed using [3H]5-HT as the radioligand using cell membranes prepared from HEK293 cells expressing recombinant 5-...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
3/20/2025
Entry Details
US Patent

Displayed 1 to 50 (of 146 total ) | Next | Last >>
Jump to: